Skip to main content
Premium Trial:

Request an Annual Quote

Tina Nova, William Rastetter, and John Stuelpnagel


Cyntellect has appointed Tina Nova to its board of directors, the San Diego-based company said last week.

Nova is currently the president, CEO, and co-founder of San Diego-based biotechnology firm Genoptix. She also co-founded Nanogen, where she served as chief operating officer and president from 1994 to 2000, and Selective Genetics, where she served as chief operating officer from 1992 to 1994. She has also held director-level positions with Ligand Pharmaceuticals.

Nova received a PhD in biochemistry from the University of California, Riverside, and conducted her postdoctoral research at New York University Medical School.

Illumina has named William Rastetter chairman of the board. Rastetter will continue full-time as the executive chairman of Biogen Idec. Before the 2003 merger between Idec Pharmaceuticals and Biogen, he was chairman and CEO of Idec, where he had served since 1986. Rastetter has also been employed by Genentech, and was an associate professor of chemistry at the Massachusetts Institute of Technology. He has been an Illumina board member since 1998.

Illumina also said that John Stuelpnagel has been promoted to the newly created position of chief operating officer. Stuelpnagel is one of Illumina’s founders, Jay Flatley, Illumina’s president and CEO, noted in a statement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.